Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study

Athanassiou, Panagiotis; Psaltis, Dimitrios; Georgiadis, A.; Katsifis, Gikas; Theodoridou, Athina; Gazi, Souzana; Sidiropoulos, Prodromos; Tektonidou, Maria G; Bounas, Andreas; Kandyli, Anna; Vounotrypidis, Periklis; Sakellariou, G; Vassilopoulos, Dimitrios; Huang, Zhiping; Petrikkou, Evangelia; Boumpas, Dimitrios T.

doi:10.1007/s00296-023-05376-5

Cited by 1 publication

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[11,12] Several clinical trials have clarified the good efficacy of golimumab in treating RA, AS, and PsA. [13,14] Etanercept, which binds to soluble TNF-α or transmembrane TNF-α, is the first TNFi permitted by the United States Food and Drug Administration for rheumatic diseases. [15,16] Although golimumab and etanercept both exhibit good efficacy in treating rheumatic diseases, the evidence focusing on their patient perceptions (such as treatment improvement and injection experience) is still insufficient.…”

Section: Introductionmentioning

confidence: 99%

Patient self-reported experience and satisfaction with golimumab and etanercept treatments for rheumatic diseases: A cohort study

Xia,

Zhou,

Gao

et al. 2024

Medicine

View full text Add to dashboard Cite

Golimumab and etanercept both exhibit good efficacy in treating rheumatic diseases, while the patient self-reported measurement of treatment improvement and injection experience lacks sufficient evidence. Hence, this study aimed to compare the satisfaction with disease improvement and injection experience and the level of injection site reactions (ISRs) between golimumab-treated and etanercept-treated patients with rheumatic diseases. A total of 312 patients with rheumatic diseases were serially enrolled. Among them, 158 patients received golimumab (golimumab group); the other 154 patients were treated with etanercept (etanercept group) according to the actual disease status, physician advice, and patient willingness. Satisfaction with disease improvement was assessed using the 7-point Likert scale; satisfaction with injection experience and level of ISRs were both determined by the 5-point Likert scale. Satisfaction degrees with global injection experience (P = .025), injection device (P = .008), injection frequency (P = .010), and injection convenience (P = .003) were superior in the golimumab group to the etanercept group, while satisfaction degrees with global disease improvement, symptom relief, and speed of action did not vary (all P > .050) between the 2 groups. Discomfort (P = .005), swelling (P < .001), pain (P = .028), and burning (P = .035) levels were lower in the golimumab group than in the etanercept group. In addition, among 56 patients with a history of tumor necrosis factor inhibitor treatment before golimumab, 40 (71.4%) patients preferred golimumab to other tumor necrosis factor inhibitor. After switching to golimumab treatment, the level of ISRs in most patients was reduced or comparable. Golimumab achieves a satisfying injection experience and relieves the level of ISRs over etanercept in patients with rheumatic diseases.

show abstract